课题基金 / 基金详情

项目摘要

项目成果

ZHONGMIN ALEX MA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):1型糖尿病(T1D)是一种由胰腺β细胞选择性破坏引起的自身免疫性疾病。导致T1D的病因步骤是复杂的、不明确的和有争议的。我们的长期目标是阐明β细胞特异性自身抗原在遗传易感个体中可用以触发自身免疫的机制。细胞凋亡是一种程序性的、生理的细胞死亡形式。凋亡程序的最终目的是清除凋亡细胞,防止其成分释放。如果不能及时这样做,就会导致炎症和自身免疫的严重后果。最近的研究表明,凋亡细胞是潜在的自身抗原储存库,可能启动和驱动易感宿主的全身自身免疫。研究表明,在自身免疫性NOD小鼠中,生理性β细胞死亡触发树突状细胞(dc)启动自身反应性T细胞。NOD小鼠中dc对死亡细胞的摄取令人惊讶,因为巨噬细胞被认为是清除凋亡细胞碎片的专家,这表明NOD小鼠中死亡β细胞的清除受损。根据这些观察结果,我们假设,在幼年NOD小鼠或易感人类中,经历发育性凋亡的β细胞未能释放“找我”信号或呈现“吃我”信号,导致凋亡的β细胞清除缺陷,随后导致释放免疫原性细胞内成分,触发自身免疫。Ca2+独立PLA2 (iPLA2)是产生溶血磷脂酰胆碱(LPC)的关键参与者,作为凋亡细胞吸引吞噬细胞的“寻找我”信号。本研究的目的是验证一个新的假设,即iPLA2不能产生“找我”信号LPC导致凋亡的β细胞清除缺陷,这使得β细胞特异性自身抗原易于易感个体发生T1D。具体目的是:1)验证iPLA2在凋亡的β细胞释放趋化因子LPC募集巨噬细胞中发挥重要作用的假说;2)验证NOD小鼠体内iPLA2水平降低导致凋亡的β细胞无法清除,从而产生β细胞特异性自身抗原的假说。通过开展这项研究,我们将能够阐明激活和促进T细胞入侵胰岛以特异性杀死β细胞的关键事件,并制定防止T1D启动自身免疫的治疗策略。通过开展这项研究,我们将能够阐明激活和促进T细胞入侵胰岛以特异性杀死β细胞的关键事件,并制定防止T1D启动自身免疫的治疗策略。
英文摘要
DESCRIPTION (provided by applicant): Type 1 diabetes (T1D) is an autoimmune disease resulting from a selective destruction of the pancreatic beta-cells. The etiologic steps leading to T1D are complex, unclear, and controversial. Our long-term goal is to elucidate the mechanisms by which beta-cell specific autoantigens are made available in the genetically susceptible individuals to trigger the autoimmunity. Apoptosis is a programmed and physiological form of cell death. The ultimate objective of apoptotic program is to remove apoptotic cells to prevent release of their components. Failure to do so promptly has serious consequences for inflammation and autoimmunity. Recent studies have implicated apoptotic cells as being potential reservoirs of autoantigens that might initiate and drive systemic autoimmunity in susceptible hosts. It has been shown that physiological beta-cell death triggers priming of self-reactive T cells by dendritic cells (DCs) in autoimmune NOD mice. The uptake of dying cells by DCs in NOD mice came as a surprise because macrophages are thought to be the specialists in clearing apoptotic cellular debris, suggesting the impaired clearance of dying beta-cells in NOD mice. In light of these observations, we hypothesize that failure to release "find-me" signals or to present the "eat-me" signals by beta-cells undergoing developmental apoptosis in juvenile NOD mice or susceptible humans results in defective clearance of apoptotic beta-cells, which subsequently results in release of immunogenic intracellular components triggering autoimmunity. Ca2+independent PLA2 (iPLA2) is key player in generating lysophosphatidylcholine (LPC) as a "find-me" signal by apoptotic cells to attract phagocytes. The goal of this study is to test a novel hypothesis that failure to produce "find-me" signal LPC by iPLA2 leads to the defective clearance of apoptotic beta-cells, which makes beta-cell specific autoantigens available predisposing to T1D in the susceptible individuals. The specific aims are to: 1) test the hypothesis that iPLA2 plays an important role for apoptotic beta-cells to release chemotactic factor LPC to recruit macrophages and 2) test the hypothesis that the decreased level of iPLA2 in NOD mice leads to failure to clear apoptotic beta-cells, which makes beta- cell specific autoantigens available. By conducting this study, we will be able to elucidate the critical events that activate and promote T cell invasion of the islets to specifically kill beta-cell and to develop therapeutic strategy preventing the initiation of autoimmunity in T1D. By conducting this study, we will be able to elucidate the critical events that activate and promote T cell invasion of the islets to specifically kill beta-cell and to develop therapeutic strategy preventing the initiation of autoimmunity in T1D.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of DT-110 as an oral therapeutic for type 2 diabetes
  • 批准号:
    9046798
  • 项目类别:
  • 资助金额:
    $76.59万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
Development of DT-109 as an oral therapeutic for type 2 diabetes
  • 批准号:
    8830889
  • 项目类别:
  • 资助金额:
    $22.5万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
Development of DT-110 as an oral therapeutic for type 2 diabetes
  • 批准号:
    9146926
  • 项目类别:
  • 资助金额:
    $72.49万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
PROTECTION OF PANCREATIC BETA-CELLS BY GROUP VIA PHOSPHOLIPASE A(2)
  • 批准号:
    8361459
  • 项目类别:
  • 资助金额:
    $0.83万
  • 财政年份:
    2011
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: